QNCX
Quince Therapeutics, Inc.
31.70$
+8.1%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Income Statement
All figures per share in USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.78 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| – | – | – | – | – | – | – | – | – | – | – | – | 0.58 | 0.59 | 0.58 | 0.56 | 0.25 | 0.52 | 0.22 | 0.23 | 0.09 | 0.01 | – | – | 1.41 | 0.20 | 0.40 | 0.07 | 0.15 | 0.15 | 0.13 | – | 0.14 | 9.62 | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | -0.58 | -0.59 | -0.58 | -0.56 | -0.25 | -0.52 | -0.22 | -0.23 | -0.09 | -0.01 | – | – | -1.41 | -0.20 | -0.40 | -0.07 | -0.15 | -0.15 | -0.13 | – | -0.14 | -9.62 | – | |
| 22.39 | 21.21 | 21.25 | 28.73 | 37.10 | 53.80 | 61.50 | 74.52 | 101.76 | 95.68 | 115.18 | 107.55 | 113.85 | 99.50 | 94.32 | 102.21 | 84.67 | 44.35 | 13.76 | 15.32 | 18.02 | 7.53 | 7.93 | 0.08 | 17.21 | 19.25 | 22.78 | 26.93 | 37.07 | 28.07 | 29.96 | 45.23 | 27.33 | 0.89 | 5.38 | |
| 3.22 | 3.31 | 5.42 | 6.92 | 9.61 | 18.66 | 17.26 | 21.72 | 24.61 | 28.43 | 33.43 | 33.88 | 43.91 | 47.75 | 51.32 | 55.97 | 60.44 | 55.80 | 24.40 | 19.65 | 21.34 | 23.56 | 25.85 | 0.11 | 23.12 | 21.79 | 16.82 | 19.80 | 21.80 | 14.32 | 12.16 | 13.05 | 17.03 | 2.71 | 4.53 | |
| 25.61 | 24.53 | 26.67 | 35.65 | 46.71 | 72.46 | 78.75 | 96.24 | 126.38 | 124.11 | 148.61 | 141.42 | 157.76 | 147.25 | 145.64 | 158.19 | 145.10 | 100.15 | 42.79 | 34.97 | 72.27 | 31.09 | 33.79 | 0.19 | 52.16 | 130.83 | 27.17 | 46.66 | 67.63 | 42.24 | 49.79 | 58.27 | 44.22 | 13.01 | 19.65 | |
| -25.61 | -24.53 | -26.67 | -35.65 | -46.71 | -72.46 | -78.75 | -96.24 | -126.38 | -124.11 | -148.61 | -141.42 | -157.76 | -147.25 | -145.64 | -158.19 | -145.10 | -100.15 | -42.79 | -34.97 | -72.27 | -31.09 | -33.79 | -0.19 | -52.16 | -130.83 | -27.17 | -46.73 | -67.63 | -42.39 | -49.79 | -58.27 | -44.36 | -13.01 | -19.66 | |
| 5.56 | 3.32 | 3.28 | 3.45 | 3.03 | 3.88 | 5.30 | 4.24 | 4.83 | 4.48 | 2.75 | 2.01 | 1.54 | 0.20 | 0.19 | 446.13 | 0.48 | 0.89 | 1.69 | 2.06 | 2.53 | – | – | – | 2.11 | – | – | 13.54 | – | – | – | – | 2.36 | – | – | |
| -31.34 | -28.84 | -23.40 | -32.20 | -43.68 | -68.58 | -73.45 | -92.00 | -121.55 | -119.63 | -145.86 | -139.41 | -156.22 | -147.05 | -145.84 | -157.21 | -143.63 | -103.79 | -44.48 | -30.63 | -69.74 | -27.21 | -29.67 | -0.21 | -51.70 | -128.52 | -25.39 | -57.56 | -68.20 | -68.47 | -50.00 | -130.33 | 122.06 | -12.30 | -15.43 | |
| 5.73 | 4.32 | -3.28 | -3.45 | -3.03 | -3.88 | -5.30 | -4.24 | -4.83 | -4.48 | -2.75 | -2.01 | -1.54 | -0.20 | 0.19 | 446.13 | -1.47 | -1.75 | 1.69 | 1.57 | -1.38 | -4.48 | -5.10 | – | 0.14 | 0.17 | 0.06 | 0.03 | 0.21 | 0.29 | -0.17 | – | -21.31 | 0.01 | – | |
| -31.34 | -28.84 | -23.40 | -32.20 | -43.68 | -68.58 | -73.45 | -92.00 | -121.55 | -119.63 | -145.86 | -139.41 | -156.22 | -147.05 | -145.84 | -157.21 | -143.63 | -102.04 | -44.48 | -30.63 | -68.35 | -27.21 | -29.67 | -0.21 | -51.84 | -128.68 | -25.45 | -57.59 | -68.41 | -68.75 | -49.83 | -141.62 | 143.37 | -12.31 | -15.08 | |
| -25.71 | -24.44 | -23.30 | -31.98 | -46.56 | -72.21 | -78.31 | -91.44 | -125.79 | -123.57 | -148.04 | -126.98 | -157.18 | -146.46 | -145.25 | -156.65 | -143.38 | -103.27 | -37.94 | -30.40 | -39.26 | -27.20 | -29.67 | – | -40.14 | -40.83 | -39.20 | -57.49 | -58.72 | -68.32 | -41.99 | -58.13 | 122.20 | -12.30 | -11.79 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.